BNET Industries
Bristol-Myers Squibb Co. (BMY) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $19.3B
- Profit
- Dec 31 2007
- $2.1B
- Market Cap
- Jul 23 2008
- $43.3B
Latest News and Analysis
Bristol Comes Out Swinging at Lilly Clot Drug
By Ransdell Pierson NEW YORK (Reuters) - Bristol-Myers Squibb Co BMY, which sells leading blood clot preventer Plavix, on Thursday dismissed Eli Lilly and Co's LLY rival Effient drug as a "niche" product that has harmed or failed to help three groups ...
Bristol Profit Beats Forecasts, Helped By Plavix
NEW YORK (Reuters) - Bristol-Myers Squibb Co BMY on Thursday reported second-quarter earnings that beat expectations, fueled by higher sales of its prescription drugs, including blood-clot preventer Plavix. The company earned $764 million, or 38 cents per share, compared with $706...
Seven High-Yielding ETFs
Thomas Smicklas submits: Back from Key West thirty six hours late, thanks to Delta. I had the opportunity to read lots of financial clutter in paradise - a tedious task the Keys made pleasant. Between the Mohitos,fresh fish and other assorted culinary delights, I navigated a conclusion that earning a...
Earnings Preview: Bristol Myers Squibb
Bristol Myers Squibb BMY is expected to report Q2 earnings before market open Thursday, July 24, with a conference call scheduled for 10:30 am ET.Guidance Analysts are expecting a profit of 40c on revenue of $5.09B. The consensus range for EPS is 38c to 42c, with a revenue range of...
Merck Rallies on New Migraine Drug
Mike Huckman submits: On another ugly day for the stock markets on Friday, beaten down shares of Dow component Merck MRK rallied. The stock started picking up steam after the news broke late Friday morning that its late-stage experimental migraine headache drug essentially works just as well as an...
Bristol-Myers Could Be an Acquisition Target: Bernstein
(Reuters) - Drugmaker Bristol-Myers Squibb Co BMY could be an acquisition target as the industry gets closer to losing exclusivity on several leading drugs, said a Sanford C. Bernstein analyst, who upgraded the stock to "outperform" from "market-perform." "BMY could ultimately...
Troubles With Lilly's Effient Empire
Mike Huckman submits: Tree huggers (just a colloquialism, not a dig) will be glad to know that biopharmaceutical companies submit their Food and Drug Administration filings for drug approval electronically these days. Dr. Tony Ware, the head of Eli Lilly's LLY cardiovascular unit, says his people tell him that...
22 Stocks Going Ex-Dividend in Early July
Stockerblog submits: I've received questions recently about all the stock dividend dates, so I thought I would clarify them for you. In addition, for those who are interested in 'buying dividends,' I have listed the stocks going ex-dividend during the first two weeks of July. Here's what each of...
Pfizer Makes a Deal, Wyeth and Elan Release Alzheimer's Drug Results
Mike Huckman submits: Last week, Pfizer PFE made a major announcement regarding the world's top-selling statin, Lipitor. Pfizer struck a deal with the Indian generic drugmaker Ranbaxy to ward off the threat of generic competition for Lipitor until late 2011. I know there were a lot of market pressures...
Analyst Notes: Lilly Gets A Lift, Pfizer Goes Pfft
Mike Huckman submits: Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's PFE oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold. But Eli Lilly LLY is the biggest dollar and percentage...
Pfizer (PFE), Bristol Myers Squibb (BMY)
Julie catches up with participants of the big pharma-sponsored New York AIDS Walk.
Bristol-Myers Squibb Co. Q1 2008 Earnings Call Transcript
Bristol-Myers Squibb Co. Q1 2008 Earnings Call Transcript
Bristol-Myers Squibb Co. Q4 2007 Earnings Call Transcript
Bristol-Myers Squibb Co. Q4 2007 Earnings Call Transcript
Bristol-Myers Squibb Q3 2007 Earnings Call Transcript
Bristol-Myers Squibb Q3 2007 Earnings Call Transcript
Bristol-Myers Squibb Q2 2007 Earnings Call Transcript
Bristol-Myers Squibb Q2 2007 Earnings Call Transcript
Improving Environmental Performance
As a leading pharmaceutical company, Bristol-Myers Squibb's mission is ?to extend and enhance human life. The company's core values, as embodied in the Bristol-Myers Squibb Pledge, focus on sustaining and improving the lives of people throughout the world. We feel that our support of this document is tangible evidence of...
global strategic sourcing
Article discusses a case of Bristol-Myers that focus on how the organization plans to deliver its billion in cost savings. Bristol-Myers Squibb has been sourcing strategically since 1996. Between 1996 and 2002, the company's Glob
Compressed Air System Renovation Project Improves Production at a Food Processing Facility
Bristol-Myers Squibb is a diversified, worldwide health and personal care company whose main products are pharmaceuticals, consumer medicines, beauty care, nutritional supplements, and medical devices. The Evansville plant conducted an evaluation of its plant with some technical assistance from an independent consultant to determine how to best improve the system....
Additional Resources
Mid-Atlantic Bio to be Held October 22-24 in Dulles, Va
Speakers to Include Nobel Laureate Kary Mullis; FDA Commissioner Andrew C. von Eschenbach; Bristol-Myers Squibb Senior Vice President Jeremy Levin; and Merck Research Site Head Lex Van der Ploeg DULLES, Va. -- The 2008 Mid-Atlantic Bio conference (http://midatlanticbio.org) today announced that Kary Mullis, Ph.D., the Nobel Prize-winning chemist...
*Revised* Analyst Reports for First Horizon National Corporation, Bristol-Myers Squibb Company, Continental Airlines Inc., and Goldcorp Inc.
MaybachFinancial.com is one of the fastest growingindependent and unbiased research firms in the world. Through our numerouspartnerships with many of the top investment minds in the world, we provideresearch on companies making a move in the markets. Investors seekinggenuine analyst opinions on their investments for First Horizon NationalCorporation (NYSE: FHN),...
- Next »
- page 1 of 181
- « Previous
Sort byClose
- Incorporated: 1933
- CEO: Mr. James M. Cornelius
Bristol-Myers Squibb is a biopharmaceutical and related health care products company. Co. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and related health care products. As of Dec 31 2007, Co. had three reportable segments: Pharmaceuticals, Nutritionals and ConvaTec. The Pharmaceuticals segment consists of the global pharmaceutical/biotechnology and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals, primarily an infant formula and children's nutritionals business. The ConvaTec segment consists of ostomy, wound and skin care business.
Key Competitors
Bristol-Myers Squibb Co. Company Info
Board of Directors
Mr. James M. Cornelius
Chairman
Dr. Robert Sanders Williams
Mr. Lewis B. Campbell
Lead Director
Mr. Louis J. Freeh
Dr. Laurie H. Glimcher M.D.
Mr. Michael Grobstein
Mr. Leif Johansson
Mr. Alan J. Lacy
Dr. Vicki L. Sato Ph.D.
Mr. Togo D. West Jr.
Contact Information
345 Park Avenue
New York, NY
212 546-4000